Biotech

During 2022, Switzerland’s biotech industry again showed its resilience by adjusting to geopolitical disruptions while continuing to play a key role in driving global healthcare innovation. The Swiss biotech companies overall recorded revenues of CHF 6.8 billion.

The Covid-19 pandemic has shown the vulnerability of the world to airborne viruses, the outbreaks of which are very difficult to contain. This pandemic is certainly not the last, as a study published in the journal Nature shows that the loss of biodiversity

Many large investors allocate huge funds for biotechnological developments. Even before the pandemic, Bill Gates, Jeff Bezos and others had been investing in bio-startups for several years. After the appearance of COVID-19, interest in the pharmaceutical industry increased several times.

Biotechnologies are one of the key segments of the modern high-tech economy, a capacious and fast-growing global market. According to experts (Researchandmarkets), the projected volume of this market for 2022 is estimated at 1.4 trillion US dollars